Wix.com enters the week with a rare split personality: options traders are more defensively positioned than at almost any point in the past year, yet shorts are actually covering — a divergence that makes the current setup more nuanced than the 4% single-day drop might suggest.
Options positioning is the sharpest signal this week. The put/call ratio jumped to 1.42, more than 2.5 standard deviations above its 20-day average of 1.21 — a reading that places defensive hedging demand at its most elevated level relative to recent norms. That's not the 52-week extreme (the ratio peaked at 2.37 at some point in the past year), but the pace of the move is notable: the PCR has risen from roughly 1.13 in late August to current levels in less than four weeks, tracking almost perfectly with the stock's slide from around $82 to $80.10. Options traders are paying up for protection into what now looks like a weakening tape.
Short interest tells a less aggressive story. Bears have been covering, not adding. SI has dropped nearly 15% over the past week to 12.1% of the free float — still high in absolute terms, but moving in the wrong direction for the bear case. The borrow market reflects this retreat: cost to borrow has fallen to just 0.68%, down over 15% on the week, and availability has loosened sharply to around 119% of outstanding short interest, up from roughly 84% a week ago. The 52-week low on availability was 8.8% — the current reading is a world away from squeeze territory. Covering, not capitulation, is the cleaner read on the short-side dynamic.
The Street is split, but nudging constructively. Needham raised its target from $80 to $95 Tuesday while maintaining a Buy, a move that matters given the stock closed at $80.10 on the day — the new target sits almost exactly 19% above the close. UBS lifted its neutral-rated target from $66 to $75 earlier in the week. Both moves follow a cluster of post-August earnings upgrades where most houses raised targets, though the starting points varied dramatically: RBC Capital went from $45 to $60 while maintaining Sector Perform, and Wells Fargo moved from $46 to $64 on an Equal-Weight. Evercore ISI stands out as the outlier — it cut its Outperform target from $120 to $95 on August 5, a significant trim even for a bull. The mean target is $79.65, almost exactly in line with the current price, which tells you the Street is not uniformly bearish but is struggling to build conviction on direction. The ORTEX short score sits at 70.8, in the bottom 4th percentile of the universe — meaning the data flags this as one of the more heavily shorted and pressured names in the system.
The bull case rests on Wix's partner revenue growth (cited at $203M) and its Base44 business solutions unit, where ARR reportedly hit $59M by end of 2025 with projections of $100M in Q1. Core revenue growth of roughly 8% year-on-year (ex-Base44) gives bulls a growth story to work with. The bear case is starker: the stock has dropped roughly 56% over the trailing twelve months, and the concern is structural — AI disruption to legacy web-creation platforms, gross margin erosion, and a slowdown in premium subscriber additions. EV/EBITDA of 8.8x and a PE of 12.8x are not stretched for a software name, but they're only a bargain if the margin trajectory stabilises.
Ownership flows add a layer of complexity. Columbia Management (via Ameriprise Financial's 13G/A filing) reported a stake of roughly 20.4% as of June — the dominant institutional position. Senvest trimmed by 836,000 shares to 6.97% as of June 30. Wellington and Millennium both filed amended 13Gs in August showing reductions from above 6% to 3.7% and from 5.2% to 1.8% respectively — meaningful exits. On the insider side, the CEO and the full C-suite (President, CFO, CMO, CTO) all sold small tranches on September 1 at $95, above the current $80 price. The CEO did purchase a matched parcel the day before at $59.89, but the net 90-day insider flow is a sale of approximately $3.2M. None of the trades carry a 10b5-1 designation in the data — though the matching buy/sell structure may reflect a share-delivery and same-day sale around a vesting event rather than a pure discretionary sale.
The next scheduled print is November 18. Given that the August 5 earnings release sent the stock up 13.6% on the day and 17.4% over the following week, while the prior release produced an 8.8% single-day loss, the reaction history is wide. What to watch between now and then is whether the PCR normalises as the stock stabilises, or whether defensive positioning continues to build even as short sellers step back — that divergence will say more about conviction than any single data point.
See the live data behind this article on ORTEX.
Open WIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
